Piramal Pharma Board Approves FY26 Results; Re-appoints 4 Directors

Piramal Pharma's Board of Directors, at its meeting on April 28, 2026, approved the Audited Financial Statements and Results (Standalone & Consolidated) for the quarter and financial year ended March 31, 2026. The Board also approved the re-appointment of four key directors, subject to shareholder approval. Ms. Nandini Piramal was re-appointed as Whole-Time Director, Executive Director, and Chairperson for three years from April 1, 2027. Mr. Peter DeYoung was re-appointed as Whole-Time Director and Executive Director for three years from October 6, 2026. Mr. Sridhar Gorthi and Mr. Peter Stevenson were both re-appointed as Non-Executive, Independent Directors for a second term of five years from March 30, 2027, with Mr. Stevenson continuing post 75 years of age.